BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 35472554)

  • 1. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
    Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
    Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
    Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
    Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
    Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
    Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
    Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
    Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine.
    Sureshchandra S; Lewis SA; Doratt BM; Jankeel A; Coimbra Ibraim I; Messaoudi I
    JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel.
    Gordon OM; Terpilowski M; Dulman R; Keller MD; Burbelo PD; Cohen JI; Bollard CM; Dave H
    Pediatr Hematol Oncol; 2022 Sep; 39(6):571-579. PubMed ID: 35135442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
    Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
    Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.